Effect of the Combination Therapy of Etidronate and Atorvastatin on Atherosclerotic Abdominal Aortic Plaques Detected by Magnetic Resonance Imaging - Prospective Open Label Trial-

Effect of the Combination Therapy of Etidronate and Atorvastatin on Atherosclerotic Abdominal Aortic Plaques Detected by Magnetic Resonance Imaging - Prospective Open Label Trial- - Aortic Plaques Prevention Trial by Etidronate and Atorvastatin

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003756

Enrollment

Registered

2010-06-15

Start date

2006-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperlipidemia, Diabetes, Hypertension, Osteoporosis

Interventions

Atorvastatin + Etidronate (ATR+ETD) group Janu. 2006-Apr.2008 Atorvastatin (ATR) group Jan. 2006-Apr.2008

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Pulse Wave Velocity > 1800 carotid artery echo: plaque score > 3 200 > LDL cholesterol > 160mg/dl Not take an improving drug of lipid metabolism for 3 months. Not take an improving drug of osteoporosis for 3 months

Exclusion criteria

Exclusion criteria: The patients who have psychic disturbance, Collagen disease, liver renal dysfunction, heart disorder, cerebrovascular disorder, and or serious complications. The patients who were decided that participation is inappropriate for them by chief physician.

Design outcomes

Primary

Measure	Time frame
The changing rate (%) of hyperplasia in Maximal Wall Thickness after one year ...ATR + ETD group vs. ATR group	—

Secondary

Measure	Time frame
The changing rate (%) of Total Vascular Area and Lumen Area after one year The changing rate (%) of LDLchol value after one year ...ATR + ETD group vs. ATR group,	—

Countries

Japan

Contacts

Public ContactTetsuya Kawahara

Niigata Rosai Hospital Endocrinology and Metabolism

k-tetsuy@niirou.jp025-543-3123

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026